Membranous Nephropathy (MN) is among the most common causes of nephrotic syndrome in adults without diabetes. If left untreated, it can progress to kidney failure. Depending on the absence or presence of associated conditions, MN is traditionally classified as primary (“idiopathic”) or secondary. Secondary MN (sMN) is related to underlying conditions such as malignancies, infections (e.g., hepatitis B or C), certain medications, or autoimmune conditions (e.g., systemic lupus erythematosus). Primary MN (pMN) accounts for 70-80% of MN cases and is characterized by immune complex deposits at the glomerular basement membrane, leading to damage to the filtration barrier and subsequent proteinuria. Recent studies have shown that in approximately 70% of patients with primary MN, the immune complexes consist of autoantibodies against the podocyte protein M-type phospholipase A2-Receptor (PLA2R). This discovery has improved diagnostic laboratory accuracy and guided therapeutic approaches.
Precision Anti-PLA2R Quantification for Membranous Nephropathy